Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.18

-1.4%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mudcat who wrote (27987)	2/7/1999 5:28:00 PM
From: Andrew Cooke	Read Replies (2) of 32384

Most medical professional liability insurers' policies would cover off label prescribing; my firm (which does a great deal of med mal defense) is currently defending providers in Diet Drug Litigation (coverage provided by med mal insurers). However, your question is a good one - as it does not seem unreasonable that policy language may change more now to exclude some off-label prescribing. I am not involved in the DDL, but do defend manufacturers in product liability matters. The interesting thing about the DDL in my state is that both manufacturers and docs have been sued - the docs on both product liability and med mal grounds. With respect to Phen Phen and Redux, it was probably $$$ and patient wants that most encouraged off-label prescribing - for those docs who prescribed the combo frequently, they did not apparently anticipate any legal ramifications from off-label prescribing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next